Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea

American Journal of Hematology

Volumn 76, Issue 4, 2004, Pages 343-347

  Conran, Nicola ^a   Fattori, André ^a   Saad, Sara T O ^a   Costa, Fernando F ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Adhesion molecules; Endothelium; Hydroxyurea; Sickle cell disease

Indexed keywords

HYDROXYUREA; INTERCELLULAR ADHESION MOLECULE 1;

ADULT; ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SICKLE CELL ANEMIA; VASCULAR ENDOTHELIUM;

ADULT; ALPHA-THALASSEMIA; ANEMIA, SICKLE CELL; CELL ADHESION; CHILD; FEMALE; FETAL HEMOGLOBIN; HUMANS; HYDROXYUREA; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; SOLUBILITY; VASCULAR CELL ADHESION MOLECULE-1;

EID: 3342982985     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20129     Document Type: Article

References (15)

1. Hebbel RP. Perspectives series: cell adhesion in vascular biology. Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest 1997;99:2561-2564.
2. Fadlon E, Vordermeier S, Pearson TC, et al. Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood 1998;91:266-274.
3. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997;337:1584-1590.
4. Springer TA. Adhesion receptors of the immune system. Nature 1990;346:425-434.
5. Shiu YT, Udden MM, McIntire LV. Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells. Blood 2000;95:3232-3241.
6. Gladwin MT, Shelhamer JH, Ognibene FP, et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol 2002;116:436-444.
7. Duits AJ, Pieters RC, Saleh AW, et al. Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. Clin Immunol Immunopathol 1996;81:86-98.
8. 2 production of polymorphonuclear neutrophils from patients with sickle cell anemia. Blood 2002;99:2297-2303.
9. Saleh AW, Hillen HF, Duits AJ. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Acta Haematol 1999;102:31-37.
10. Hubbard AK, Rothlein R. Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades. Free Radic Biol Med 2000;28:1379-1386.
11. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317-1322.
12. Vichinsky E. New therapies in sickle cell disease. Lancet 2002;360:629-631.
13. Gladwin MT, Schechter AN. Nitric oxide therapy in sickle cell disease. Semin Hematol 2001;38:333-342.
14. Zampolli A, Basta G, Lazzerini G, Feelisch M, De Caterina R. Inhibition of endothelial cell activation by nitric oxide donors. J Pharmacol Exp Ther 2000;295:818-823.
15. Berendji-Grun D, Kolb-Bachofen V, Kroncke KD. Nitric oxide inhibits endothelial IL-1[beta]-induced ICAM-1 gene expression at the transcriptional level decreasing Sp1 and AP-1 activity. Mol Med 2001;7(11):748-754.